The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Total Raised

$11M

Investors Count

3

Deal Terms

1

Bikam Pharmaceuticals Funding, Bikam Pharmaceuticals Valuation & Bikam Pharmaceuticals Revenue

2 Fundings

Bikam Pharmaceuticals's latest funding round was a Series A for $11M on November 23, 2007.

Bikam Pharmaceuticals's latest post-money valuation is from November 2007.

Sign up for a free trial to see Bikam Pharmaceuticals's valuations in November 2007 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

11/23/2007

Series A

$11M

$99M

0

FY undefined

Incubator/Accelerator

0

FY undefined

0

Date

11/23/2007

Round

Series A

Incubator/Accelerator

Amount

$11M

Investors

Valuation

$99M

Revenue

0

FY undefined

0

FY undefined

Sources

0

Bikam Pharmaceuticals Deal Terms

1 Deal Term

Bikam Pharmaceuticals's deal structure is available for 1 funding round, including their Series A from November 23, 2007.

Round

Series A

Funding Date

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

Amount Raised

$99M

Shares Authorized

Issuance Price

$99M

Dividend Rate

$99M

Liquidation Preferences

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Bikam Pharmaceuticals Investors

3 Investors

Bikam Pharmaceuticals has 3 investors. CHL Medical Partners invested in Bikam Pharmaceuticals's Series A funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

11/23/2007

11/23/2007

1
Series A

Venture Capital

Connecticut

00/00/0000

00/00/0000

Fidelity Investments

Subscribe to see more

Diversified Financial Services

Massachusetts

Sid Martin Biotechnology Incubator

Subscribe to see more

Incubator/Accelerator

Florida

First funding

11/23/2007

00/00/0000

Last Funding

11/23/2007

00/00/0000

Investor

Fidelity Investments

Sid Martin Biotechnology Incubator

Rounds

1
Series A

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Diversified Financial Services

Incubator/Accelerator

Location

Connecticut

Massachusetts

Florida

You May Also Like

Oligomerix Logo
Oligomerix

Oligomerix is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity. The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

B
BrainCells

BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.

S
Selectx Pharmaceuticals

SelectX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of small molecule antimicrobials and other therapeutics for unmet medical needs through the application of its Genetic Chemistry platform.

K
Kemia

Kemia discovers and develops new, oral small molecule medicines for well-validated, clinically significant targets. Kemia applies proprietary chemistries and medicinal chemistry experience to two large and as yet underdeveloped classes of small molecule drug opportunities -- alpha helix interactions and allosteric kinase inhibitors. These target classes include numerous potential drug discovery targets across major disease areas including inflammation, cancer, HIV, diabetes and bone diseases.

H
Halsa Pharmaceuticals

Halsa Pharmaceuticals is a biotechnology company developing therapeutics for the treatment of obesity, diabetes, cachexia and other metabolic diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.